Catalyst
Slingshot members are tracking this event:
Lexicon Announces FDA Priority Review of New Drug Application for Telotristat Etiprate for the Treatment of Carcinoid Syndrome; PDUFA Target Action Date extended to February 28 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LXRX | Community voting in process | |||||
Additional Information
“The granting of priority review by the FDA underscores the need for improving the lives of the patients and caregivers who live with carcinoid syndrome on a daily basis,” said Lexicon President and Chief Executive Officer, Lonnel Coats. “If approved, telotristat etiprate would be the only approved therapy for patients who are no longer able to control their carcinoid syndrome with the current standard of care alone.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 28, 2016
Occurred Source:
http://www.lexpharma.com/media-center/news/623-xermelo
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Carcinoid Syndrome, Telotristat Etiprate
